|
|
Oxford Nanopore Technologies made an announcement this week , 2017 The company's revenue tripled , This was mainly due to the increased sales of its nanopore sequencers and consumables. |
In a document providing the House of Commons with information on annual reports and earnings of British companies, Oxford Nanopore said its revenue grew 204 percent in 2017, from 4.5 million pounds in 2016 to 13.8 million pounds ($18.4 million) in 2017. |
Among the regions, revenue in the United States was approximately 4.5 million pounds, revenue in Europe excluding the UK was 4.1 million pounds, revenue in the UK was 1.3 million pounds, and revenue in other regions was 3.9 million pounds. |
The company said that in the past year, the number of customers and consumables usage have increased. Customers are using nanosequencing technology for a variety of applications, including rapid pathogen analysis, drug resistance identification, brain tumor tissue analysis, soil analysis, plant sequencing, transcriptional analysis and environmental research. |
|
|
|
The company said the MinIon sequencer is being evaluated in a study of hospital-acquired pneumonia and is also being used to identify plant pathogens on farms in Tanzania, detect pathogens in food, and analyze wastewater. |
|
Oxford Nanopore 2017 Received more than 100 indivual GridIon Order of sequencer , GridIon It is the company's medium-sized platform , Can run up to five MinIon flow cell At last month's user conference , The company said , It is in twenty four countries have more than 100 name GridIon client. |
|
The company also expanded its production and distribution channels last year, grew its commercial team and covered new areas such as translational medicine and agriculture. The company said its commercial team now serves more than 70 countries. |
|
|
|
The company’s research and development spending fell from £38.1m in 2016 to £35m in 2017, while its administrative expenses increased from £23.6m to £33m over the same period. |
|
The company's net loss narrowed to £56.6m in 2017 from £59.3m in 2016, thanks to growth in sales and margins, as well as higher research and development tax credits. |
|
As of December 31, 2017, Oxford Nanopore had cash and cash equivalents of £57.8 million. |
|
The company recently raised £100 million from investors in China, Singapore, Australia and existing investors. The funds will support its commercial expansion, including the construction of a new 35,000 square foot production facility near Oxford, expected to open in early 2019; the expansion of the commercial team; and the development of new products. |
|
In its report, the company lists five wholly owned subsidiaries: Oxford Nanotech, founded in 2011 in Cambridge, Massachusetts, provides R&D subcontracting and other services to companies in the United States; Metrichor, founded in the UK in 2013, provides analytical solutions for nanosensing devices; GenomeFoundry, founded in the UK in 2015; KK Oxford Nanotech, founded in Tokyo, Japan in 2016, mainly provides services to Japanese companies; and Oxford Nanolabs in the United Kingdom, a defunct company. |
|
Oxford Nano also said , It covered the costs of the lawsuit between the University of California and Genia Technologies. |
|
The University of California Regents filed a lawsuit in the Northern District Court of California in 2016, accusing Genia's chief technology officer Roger Chen of developing patented nanopore technology while an employee of the University of California and licensing the patent to Genia. Oxford Nanopore said the two parties have agreed to a settlement and are currently preparing a final settlement agreement, which needs to be approved by the University of California Regents and Roger Chen. |
|
Reprinted from Dingxiangtong |
